Knowledge on the use of laser as a treatment modality of ROP was shown by 39 (55.7%) participants, and the use of anti-VEGF was shown by 6 (8.6%) participants, whereas 25 (35.7%) of the participants didn’t know about the treatment modalities. The gene discussed is VEGFA; the disease is retinopathy of prematurity.